Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19327867 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | September 2025 | March 2026 | Allow | 6 | 1 | 1 | Yes | No |
| 19258335 | ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | July 2025 | December 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19048594 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | February 2025 | July 2025 | Allow | 6 | 2 | 1 | Yes | No |
| 19040329 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | January 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 18904330 | KRAS Proteolysis Targeting Chimeras | October 2024 | December 2025 | Allow | 15 | 3 | 1 | No | No |
| 18820232 | USE OF REBOXETINE TO TREAT NARCOLEPSY | August 2024 | March 2025 | Allow | 6 | 3 | 0 | Yes | No |
| 18809602 | CATALYSTS FOR SYNTHESIZING CYCLIC CARBONATES, PREPARATION METHODS AND USES THEREOF | August 2024 | August 2025 | Allow | 12 | 2 | 1 | No | No |
| 18809731 | DEVICE AND METHOD FOR PRODUCING HIGH-PRESSURE OR SUPER HIGH-PRESSURE STEAM AS BYPRODUCT FROM MALEIC ANHYDRIDE PRODUCING DEVICE | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18787536 | Systems and methods for the production of levulinic acid, furfural, and formic acid | July 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18765167 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18670653 | LOW-TEMPERATURE CONTINUOUS-FLOW PREPARATION METHOD OF BEDAQUILINE | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18657519 | READY-TO-ADMINISTER HYDROMORPHONE FORMULATIONS | May 2024 | September 2025 | Allow | 16 | 0 | 1 | Yes | No |
| 18654002 | BIMETALLIC METAL-ORGANIC FRAMEWORKS NANOSHEET BASED ON ZEOLITE IMIDAZOLE FRAMEWORK/MATERIALS OF INSTITUTE LAVOISIER TOPOLOGY AND PREPARATION METHOD AND APPLICATION THEREOF | May 2024 | October 2024 | Allow | 5 | 0 | 1 | No | No |
| 18443228 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | February 2024 | July 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18419104 | METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION | January 2024 | August 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18573904 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | December 2023 | June 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18541304 | SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES | December 2023 | August 2025 | Allow | 20 | 4 | 1 | No | No |
| 18538443 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | December 2023 | July 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18532307 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM | December 2023 | October 2025 | Allow | 22 | 2 | 0 | No | No |
| 18529306 | FORMULATIONS | December 2023 | October 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18529515 | 6-(4-HYDROXYPHENYL)-2-(2-ETHOXYETHOXY)-4-(4-METHOXYPHENYL)NICOTINONITRILE AS AN ANTIMICROBIAL COMPOUND | December 2023 | July 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18521663 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | November 2023 | April 2025 | Allow | 17 | 0 | 1 | No | No |
| 18516230 | Bromodomain Inhibitors | November 2023 | October 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18508164 | 1,4-DIVINYLPHENYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(PiPR3)2 MOIETIES WITH 8-MERCAPTOQUINOLATO CO-LIGAND AS AN ORGANIC CATALYST | November 2023 | December 2024 | Allow | 13 | 2 | 1 | No | No |
| 18386447 | COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING | November 2023 | March 2026 | Abandon | 28 | 1 | 1 | No | No |
| 18385578 | 8-((3,4-DIHYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | February 2025 | Allow | 15 | 3 | 0 | No | Yes |
| 18385561 | 8-((4-HYDROXY-3-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | June 2025 | Abandon | 19 | 4 | 0 | No | No |
| 18384771 | 8-((3-FORMYL-4-HYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | February 2025 | Allow | 16 | 3 | 0 | Yes | Yes |
| 18384785 | 8-[(2-HYDROXYNAPHTHALEN-1-YL)DIAZENYL]NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | May 2025 | Abandon | 18 | 3 | 0 | No | No |
| 18384197 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | October 2023 | March 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18383949 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | October 2023 | July 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18492874 | COMPOUNDS AND COMPOSITIONS FOR NEMATODE TREATMENT | October 2023 | November 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18492746 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | October 2023 | January 2025 | Allow | 15 | 0 | 0 | Yes | No |
| 18379559 | N-(NAPHTHALEN-1-YLCARBAMOTHIOYL)FURAN-2-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | October 2023 | December 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18484858 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | October 2023 | November 2025 | Allow | 25 | 1 | 1 | No | No |
| 18475724 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | September 2023 | February 2025 | Allow | 16 | 1 | 1 | No | No |
| 18467441 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM | September 2023 | September 2025 | Allow | 24 | 1 | 1 | No | No |
| 18464352 | SOLUTIONS FOR ENHANCING THE EFFECTIVENESS OF INSECTICIDES AND FUNGICIDES ON LIVING PLANTS AND RELATED METHODS | September 2023 | September 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18445510 | Deuterated Fluorophores | September 2023 | October 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18242203 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | September 2023 | October 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18233090 | CONTRACEPTIVE COMPOUNDS AND METHODS | August 2023 | December 2024 | Allow | 16 | 0 | 0 | Yes | No |
| 18365877 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | August 2023 | February 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18229353 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | August 2023 | July 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18363994 | CRYSTALLINE SOLID FORMS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE | August 2023 | July 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18352791 | A PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER | July 2023 | November 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18220856 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | July 2023 | July 2025 | Allow | 24 | 1 | 0 | No | No |
| 18347808 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | July 2023 | November 2024 | Allow | 16 | 0 | 0 | Yes | No |
| 18339227 | MACROCYCLIC COMPOUND AND USES THEREOF | June 2023 | May 2025 | Allow | 23 | 1 | 1 | No | No |
| 18209699 | BROMOCRIPTINE FORMULATIONS | June 2023 | December 2024 | Allow | 18 | 0 | 0 | Yes | No |
| 18206953 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | June 2023 | December 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18204566 | ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOF | June 2023 | June 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18254089 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | May 2023 | February 2026 | Allow | 32 | 1 | 0 | Yes | No |
| 18318939 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | May 2023 | December 2023 | Allow | 60 | 0 | 1 | Yes | No |
| 18318158 | METHODS, COMPOSITIONS, AND KITS ADDRESSING DEPRESSED MOOD | May 2023 | June 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18141999 | DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18307174 | SUBSTITUTED ALKYLPHENOLS AS HCN1 ANTAGONISTS | April 2023 | November 2024 | Allow | 19 | 0 | 0 | Yes | No |
| 18305611 | FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18304764 | ORGANIC ELECTRO-OPTIC CHROMOPHORES | April 2023 | March 2025 | Allow | 23 | 0 | 1 | Yes | No |
| 18137766 | CANNABINOID CONJUGATE MOLECULES | April 2023 | November 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 18304411 | Synthesis and Composition of Neurolenin D Mesylate and Related Compounds - New Drugs for the Treatment of Parasitic Nematode Infections in Humans, Animals and Plants | April 2023 | February 2026 | Allow | 34 | 0 | 1 | Yes | No |
| 18303267 | USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | Yes | No |
| 18135225 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | Yes | No |
| 18297973 | ORAL CANNABINOID PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING SLEEP DISORDERS | April 2023 | July 2023 | Allow | 3 | 0 | 0 | No | No |
| 18131052 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | April 2023 | March 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18130178 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | April 2023 | September 2024 | Allow | 17 | 0 | 1 | Yes | No |
| 18029289 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | March 2023 | December 2025 | Allow | 33 | 0 | 1 | No | No |
| 18185555 | SOLID FORMS COMPRISING AN OXIME ETHER COMPOUND, COMPOSITIONS AND METHODS OF USE THEREOF | March 2023 | May 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18121694 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | March 2023 | October 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18119564 | PROLONGED ECTOPARASITE-CONTROLLING AGENT FOR ANIMAL | March 2023 | March 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18119751 | COUMARIN COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | December 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 18117328 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | March 2023 | February 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18117257 | Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity | March 2023 | June 2025 | Abandon | 27 | 1 | 1 | Yes | No |
| 18115966 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | March 2023 | May 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18114055 | BORATE SALTS, POLYMERS AND COMPOSITES | February 2023 | July 2024 | Allow | 16 | 0 | 1 | No | No |
| 18169716 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | February 2023 | September 2024 | Allow | 19 | 1 | 0 | No | No |
| 18168583 | CRYSTALLINE FORMS OF BENZAMIDE COMPOUND AND PROCESS FOR PREPARING THE SAME | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | Yes | No |
| 18157593 | CO-CRYSTALS OF BOSCALID AND TRIAZOLES | January 2023 | July 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 18096272 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | January 2023 | April 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18152098 | DENDRILLA MEMBRANOSA COMPOUNDS, DERIVATIVES THEREOF, AND USES THEREOF | January 2023 | February 2025 | Allow | 25 | 2 | 1 | No | No |
| 18013375 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | December 2022 | November 2025 | Allow | 34 | 0 | 1 | Yes | No |
| 18003226 | CYCLOBUTYL-UREA DERIVATIVES | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18002932 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXOLINE LYSINATE, PREPARATION METHOD THEREFOR AND USE THEREOF | December 2022 | March 2026 | Allow | 38 | 1 | 1 | No | No |
| 18069943 | METHOD FOR MANUFACTURING METHYLTETRAHYDROPHTHALIC ANHYDRIDE | December 2022 | August 2024 | Allow | 60 | 3 | 0 | Yes | No |
| 18068700 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | December 2022 | January 2026 | Allow | 37 | 2 | 1 | Yes | No |
| 18011646 | USE OF COMPOSITION IN TREATMENT OF CEREBRAL STROKE | December 2022 | January 2026 | Allow | 37 | 2 | 0 | Yes | No |
| 18084307 | AMINO ACID COMPOUNDS AND METHODS OF USE | December 2022 | May 2024 | Allow | 17 | 0 | 0 | Yes | No |
| 18067456 | READY-TO-USE BARRIER AND KNOCKDOWN PESTICIDES | December 2022 | January 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18082973 | Methods of Treating Residual Lesions of Vascular Anomalies | December 2022 | May 2025 | Abandon | 29 | 2 | 0 | Yes | No |
| 18062683 | Fospropofol Salts, Methods And Compositions | December 2022 | March 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18075664 | CHEMICAL COMPOUNDS | December 2022 | December 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17990427 | CD16A BINDING AGENTS AND USES THEREOF | November 2022 | July 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 17925923 | ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOF | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18055282 | System and Method for Making Cannabinoid Nanoparticle Carrier Composition | November 2022 | August 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17983563 | CHIRAL MULTIDENTATE LIGAND, AND APPLICATION THEREOF IN ASYMMETRIC HYDROGENATION | November 2022 | October 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17982859 | CANNABINOID CONJUGATE MOLECULES | November 2022 | March 2023 | Allow | 4 | 0 | 1 | Yes | No |
| 17982779 | CANNABINOID CONJUGATE MOLECULES | November 2022 | March 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 17982233 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | November 2022 | February 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 17922790 | COMPOSITIONS OF TRYPTOPHOL DERIVATIVES AND 4-ETHYL-PHENOL DERIVATIVES, AND METHODS OF USING SAME | November 2022 | July 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17977349 | E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS | October 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17974804 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | October 2022 | May 2025 | Abandon | 30 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRAKUMAR, NIZAL S.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHANDRAKUMAR, NIZAL S works in Art Unit 1625 and has examined 2,456 patent applications in our dataset. With an allowance rate of 73.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.
Examiner CHANDRAKUMAR, NIZAL S's allowance rate of 73.1% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHANDRAKUMAR, NIZAL S receive 1.27 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHANDRAKUMAR, NIZAL S is 23 months. This places the examiner in the 85% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +23.6% benefit to allowance rate for applications examined by CHANDRAKUMAR, NIZAL S. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 35.9% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 62.3% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 154.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 90% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 93.3% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 77.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.3% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.7% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.2% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.